KRAS and non-small cell lung carcinoma: In this cohort of patients, the response rates to PD-(L)1 inhibitors were only 7.4% in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant NSCLC and 0% in patients treated with nivolumab in the CheckMate-057 phase III trial [77].